Study of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection
Study of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will
 receive VIR-2218+ VIR-3434 and will be assessed for safety, tolerability, and efficacy
Inclusion Criteria:

 -  Male or female ages 18 - <66 years

 -  Chronic HBV infection for >/= 6 months

 -  On NRTI therapy for >/= 2 months at the time of screening

 Exclusion Criteria:

 -  Any clinically significant chronic or acute medical condition that makes the
 participant unsuitable for participation

 -  Significant fibrosis or cirrhosis

 -  History or evidence of drug or alcohol abuse

 -  History of chronic liver disease from any cause other than chronic HBV infection

 -  History of hepatic decompensation

 -  History of anaphylaxis

 -  History of allergic reactions to monoclonal antibodies or antibody fragments

 -  History of immune complex disease

 -  Active infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
 hepatitis Delta virus (HDV)